

## MIT Open Access Articles

*Heterogeneity in Choice Inconsistencies among the Elderly: Evidence from Prescription Drug Plan Choice*

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

**Citation:** Abaluck, Jason, and Jonathan Gruber. "Heterogeneity in Choice Inconsistencies Among the Elderly: Evidence from Prescription Drug Plan Choice." *American Economic Review* 101.3 (2011): 377–381. © 2011 AEA

**As Published:** <http://dx.doi.org/10.1257/aer.101.3.377>

**Publisher:** American Economic Association

**Persistent URL:** <http://hdl.handle.net/1721.1/73122>

**Version:** Final published version: final published article, as it appeared in a journal, conference proceedings, or other formally published context

**Terms of Use:** Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.



## THE ECONOMICS OF THE MEDICARE PART D PRESCRIPTION DRUG PROGRAM<sup>†</sup>

### Heterogeneity in Choice Inconsistencies among the Elderly: Evidence from Prescription Drug Plan Choice

By JASON ABALUCK AND JONATHAN GRUBER\*

The Medicare Modernization Act of 2003, better known as the legislation that added the Part D prescription drug benefit to the Medicare program, represents the single most significant expansion of public insurance programs in the United States in the past 40 years. The most novel, and controversial, feature of this legislation was the use of multiple private insurance providers to deliver this new public insurance product. This unprecedented privatization of the delivery of a public insurance product raises a host of important policy questions. Primary among these is the impact of allowing choice across so many private insurance options.

While standard economic theory would suggest that allowing a wide variety of plan choices would increase welfare, a recent body of work suggests that such “choice overload” can lead to inferior decision making, as nicely reviewed in Sheena S. Iyengar and Eric Kamenica (2006). Our previous work (Jason Abaluck and Jon Gruber forthcoming) investigated the prescription drug insurance plan choices made by elders for the newly formed Part D program in 2006. In this paper, we extend that earlier analysis to consider heterogeneity in choice inconsistency.

Part D beneficiaries can choose from three types of private insurance coverage for their drug expenditures. Our study focuses on the

most important of these, standalone plans called Medicare Prescription Drug Plans (PDP). In 2006, there were 1,429 total PDPs offered throughout the nation, with most states offering about 40 PDPs. The majority of PDPs are offered by a dozen national or near national companies. Under Part D, recipients were entitled to basic coverage of prescription drugs by a plan with a structure actuarially equivalent to the following: none of the first \$250 in drug costs each year; 75 percent of costs for the next \$2,000 of drug spending (up to \$2,250 in total); 0 percent of costs for the next \$2,850 of drug spending (up to \$5,100 in total, the “doughnut hole”); and 95 percent of costs above \$5,100 of drug spending. Over 90 percent of beneficiaries in 2006, however, were not enrolled in the standard benefit design but rather are in plans with low or no deductibles, flat payments for covered drugs following a tiered system, or some form of coverage in the doughnut hole. Overall, Part D sponsors had great flexibility in terms of plan design. Many insurance companies sponsored multiple plans of differing levels of premiums and coverage generosity.

Our primary data source is a longitudinal sample of prescription drug records from the Wolters Kluwer (WK) Company. They are the largest “switch” operator in the prescription drug market: they collect the electronic claims from pharmacies and pass them on to the Pharmacy Benefit Managers (PBMs) and insurance companies that will pay the claims. WK keeps a longitudinal file that tracks prescription drug use for more than 100 million persons in the United States. They have made available to us for research purposes a longitudinal sample of prescription claims for any individuals age 65 and over in 2005. These data are crucial because they are the only available data (of which we are aware) that contain information both on specific

<sup>†</sup>*Discussants:* David Laibson, Harvard University; Claudio Lucarelli, Cornell University; Wesley Yin, Boston University; Marty Gaynor, Carnegie Mellon University.

\*Abaluck: Department of Economics, Massachusetts Institute of Technology, Cambridge MA 02139 (e-mail: abaluck@mit.edu); Gruber: Department of Economics, Massachusetts Institute of Technology, Cambridge, MA 02139 (e-mail: gruberj@mit.edu). We are grateful to Jim Hendrix, Chris Messner, Pallavi Mudumby, Steven Pieri and John Porell from Wolters Kluwer for providing data and to the National Institute of Aging for financial support under grant number R01 AG031270.

TABLE 1

	All plans			Variance improving		
	Percentage minimizing (1)	Dollars savings (2)	Percentage savings (3)	Percentage minimizing (4)	Dollars savings (5)	Percentage savings (6)
<i>All</i>	12.17	296	31.01	26.89	237	23.42
<i>Terciles of age</i>						
1	11.30	298	31.94	25.67	238	24.16
2	12.38	296	30.96	27.43	234	23.20
3	12.87	295	30.07	27.58	238	22.88
<i>Gender</i>						
F	12.73	295	30.63	27.40	236	23.20
M	11.21	299	31.66	25.98	237	23.82
<i>Terciles of 2005 expenditures</i>						
1	10.65	217	34.26	27.33	159	25.14
2	13.04	264	30.75	27.31	208	23.27
3	12.84	424	27.68	25.55	358	21.84
<i>Terciles of percent chronic drugs</i>						
1	10.46	274	33.02	25.83	214	24.81
2	12.70	326	30.05	27.12	264	22.81
3	13.30	289	30.01	27.69	231	22.69

*Notes:* The first three columns give the percentage of patients choosing the cost minimizing plan, the average savings from switching to the cost minimizing plan, and the average savings as a percentage of realized out of pocket costs from switching to the cost minimizing plan. Columns 4–6 give the same numbers, but considering only plans which are variance improving (i.e., whose variance is at least as small as the chosen plan). The percent of acute drugs is computed as the proportion of claims in 2005 for a drug which also appears in the data in 2006.

drug utilization by elders and on plan choice. Information about specific drug utilization is key because plan costs vary tremendously based on drug utilization, as we discuss below.

These data have a number of strengths and weaknesses, as described in Abaluck and Gruber (forthcoming). They provide a very large longitudinal sample of elders before and during the first year of the Part D program that is nationally representative. On the other hand, there is some imprecision in matching elders to their Part D insurance plan, and there is a high rate of sample attrition that is potentially due to switching to pharmacies outside the WK sample. In our earlier work we carefully document that this is unlikely to be driving our findings.

We match these WK data to information provided by CMS on plan details and beneficiary costs. This allows us to fully parameterize any elder's plan choice set based on his location. We have used these data to build a "cost calculator" that mimics the calculator provided on Medicare's Web site. This calculator uses a

given set of prescriptions for a given elder to compute his projected out of pocket spending in each plan available in that county. Our analysis evaluates plan choice using both the elder's actual 2006 prescription drug spending, as well as a predicted measure based on 2005 spending; the results are robust to both.

We begin by presenting basic facts on plan choice. For each individual in the data, we estimate the total cost of enrolling in each PDP plan in that county, adding both premiums and expected out of pocket costs. We then estimate the difference in total costs between the plan chosen by that individual and the lowest cost plan in that county.

Table 1 shows the share of individuals choosing the lowest cost plan available to them, and the savings to the typical elder from choosing that lowest cost plan. For the full sample, we find that only 12.2 percent of elders choose the lowest cost plan, and that the typical elder could save \$296, or 30.1 percent of his total Part D costs by choosing the lowest cost plan rather

than the plan that he did choose. Of course, individuals are not simply choosing a fixed payment stream when choosing a Part D plan; individuals who are highly risk averse may explicitly be choosing plans with higher mean expenditure to protect themselves against variance in expenditure. Yet this does not seem to be the case. Even if we include *only* plan choices where the variance is nonincreasing, over 73 percent of enrollees could have chosen a lower cost plan, and the average enrollee could have saved 23.7 percent of his Part D expenditures without raising the variance.

We next extend these results on plan choice for a wide variety of elderly subgroups. We find a strikingly flat pattern of results by age, with some suggestion of improved choice at older ages. We also find little heterogeneity by gender. When we divide the sample by 2005 drug expenditure decile, there is more heterogeneity. As 2005 drug spending rises, the dollar savings from better choices rises, while the percentage savings falls. Those in the top decile would save on average almost three times as much as those in the bottom decile from better choices, but as a share of out of pocket spending this is only 5/7 as much.

An alternative potential determinant of choice consistency could be regularity of prescription drug use. Mark Duggan and Fiona Scott Morton (2011) hypothesize that consumers may fail to take into account variation across plans in the coverage provided for acute drugs if they are not currently consuming those drugs. Our results provide weak support for this hypothesis but suggest that it is not a major driver of consumer error. We define the proportion of drugs which are chronic as the proportion of 2005 claims which are from drugs for which the consumer also has claims in 2006. Consumers are more likely to choose the cost minimizing plan if a greater proportion of their drugs are chronic: 13 percent of consumers choose the cost minimizing plan in the largest tercile of chronic drugs, while just 10 percent choose the cost minimizing plan in the lowest tercile. Nonetheless, potential cost savings vary little across tercile, ranging from 30 percent in the lowest tercile to 33 percent in the largest tercile.

We extend our analysis to control for other factors that might impact plan choice of elders by estimating a conditional logit model of plan

choice where the utility of individual  $i$  from choosing plan  $j$  is given by:

$$(1) \quad u_{ij} = \pi_j \beta_0 + \mu_{ij}^* \beta_1 + \sigma_{ij}^2 \beta_2 \\ + \mathbf{x}_j \boldsymbol{\lambda} + \boldsymbol{\xi}_{b(j)} + \epsilon_{ij},$$

where  $\pi_j$  is the premium for plan  $j$ ,  $\mu_{ij}^*$  is the expected out of pocket costs for individual  $i$  if he is enrolled in plan  $j$  given the information available at the time when he chooses,  $\sigma_{ij}^2$  is the variance of out of pocket costs for individual  $i$  if he enrolls in plan  $j$ ,  $\mathbf{x}$  represents any financial plan characteristics which impact choice,  $\boldsymbol{\xi}_{b(j)}$  is a full set of brand-specific dummies, and  $\epsilon_{ij}$  are i.i.d. type I extreme value random variables. Following Abaluck and Gruber (forthcoming), we do not use actual (noisy and endogenous) out of pocket expenditures but a predicted measure based on 2005 utilization.

We include in our model several financial plan characteristics beyond premiums, out of pocket costs, and the variance of out of pocket costs. These are: the deductible of the plan; a dummy for whether the plan covers all doughnut hole expenditures; a dummy for whether the plan covers generic expenditures in the doughnut hole only; and a cost-sharing index. We also include a measure of plan quality: the share of the top 100 drugs used by elders that is included in the plan's formulary. Other differences across brands, including different quality ratings as well as consumer tastes by brand, are absorbed by a full set of brand-specific dummy variables.

We consider three tests of "choice inconsistencies." The first is whether the coefficient on premiums and out of pocket costs are different; controlling for the risk characteristics of plans, individuals should be willing to pay exactly one dollar in additional premiums for coverage which reduces expected out of pocket costs by one dollar. The second is that  $\lambda \neq 0$ ; individuals should not care about deductibles, doughnut hole coverage or copays per se; they should care about these factors only to the extent that they impact the distribution of out of pocket costs. The third is that the coefficient on plan variance is nonnegative, which should be true for risk averse individuals. In Abaluck and Gruber (forthcoming), we develop the theoretical basis for these tests and offer compelling simulation evidence that they represent choice inconsistencies.

TABLE 2

	Premium	OOP	Variance	F-test
All	-0.5051 (0.0061)	-0.0980 (0.0015)	-0.0006 (0.0008)	$X^2(5) = 1,641, p < 0.0001$
Age 1	-0.4616 (0.0109)	-0.1105 (0.0042)	-0.0008 (0.0019)	$X^2(5) = 1,570, p < 0.0001$
Age 2	-0.4625 (0.0062)	-0.1085 (0.0024)	-0.0001 (0.0008)	$X^2(5) = 1,658, p < 0.0001$
Age 3	-0.5172 (0.0110)	-0.1162 (0.0042)	-0.0009 (0.0016)	$X^2(5) = 1,751, p < 0.0001$
Female	-0.4671 (0.0104)	-0.1109 (0.0039)	0.0002 (0.0016)	$X^2(5) = 1,726, p < 0.0001$
Male	-0.4855 (0.0078)	-0.1119 (0.0030)	-0.0008 (0.0010)	$X^2(5) = 3,176, p < 0.0001$
Expend 1	-0.6722 (0.0130)	-0.1462 (0.0223)	0.0030 (0.0021)	$X^2(5) = 2,709, p < 0.0001$
Expend 2	-0.5536 (0.0112)	-0.1473 (0.0085)	-0.0015 (0.0017)	$X^2(5) = 1,909, p < 0.0001$
Expend 3	-0.3955 (0.0105)	-0.0847 (0.0029)	-0.0009 (0.0012)	$X^2(5) = 1,421, p < 0.0001$
Acute	-0.5206 (0.0124)	-0.1076 (0.0059)	-0.0006 (0.0026)	$X^2(5) = 1,673, p < 0.0001$
Chronic	-0.4620 (0.0072)	-0.1111 (0.0026)	-0.0006 (0.0008)	$X^2(5) = 3,261, p < 0.0001$

*Notes:* This table reports the coefficients on premiums, expected out of pocket costs, and the variance of out of pocket costs from the conditional logit model in equation (1), as well as an *F*-test for the significance of financial plan characteristics. Each row indicates a separate specification. Premiums and out of pocket costs are in hundreds of dollars; the variance is multiplied by  $10^6$ . Age 1, Age 2, Age 3, Expend 1, Expend 2, and Expend 3 denote respective terciles of the age and expenditure distributions. Acute and Chronic are defined in the text. Standard errors are in parentheses.

Table 2 summarizes our key results by showing the coefficients on premium and out of pocket costs, an *F*-test of the joint significance of other plan characteristics, and the coefficient on plan variance. For the full sample, the results demonstrate the three choice inconsistencies discussed above: the responsiveness to premiums is five times as large as the responsiveness to out of pocket costs; plan characteristics continue to matter for choices even after controlling for their out of pocket cost consequences, and consumers appear unresponsive to variation across plans in the variance of out of pocket costs.

We then extend this analysis to consider whether our results are consistent across subgroups: we consider terciles of age, gender, terciles of 2005 drug expenditures, and acute versus chronic patients (where acute patients are defined as patients for whom fewer than 35 percent of claims were from drugs which were also consumed in 2006). As in the case of the

efficient frontier analysis, the results are remarkably consistent across different demographic groups. The choice inconsistencies noted above are present in all specifications, and the magnitude of the coefficients varies little.

One possible exception is individuals with higher costs in 2005. In the efficient frontier analysis, we showed that these individuals have higher absolute cost savings, and the logit analysis shows that their choices are noisier in the sense that the premium and out of pocket cost coefficients are both smaller than in other specifications, meaning that a smaller fraction of choices are explained by variation in financial characteristics. The logit result suggests that in addition to having more to lose by choosing the wrong plan, sicker individuals also choose worse (this is a difficult conclusion to establish firmly since the definition of “sick” in this case precludes a comparison of sick and healthy individuals facing identical tradeoffs).




FIGURE 1. DISTRIBUTION OF COST SAVINGS BY STATE

Finally, in Figure 1, we consider the effects by state. Once again, there is surprisingly little variation. In the vast majority of states, the average savings from switching to the lowest total cost plan are between 20 percent and 40 percent of total costs. The states in which potential cost savings are less than 20 percent are also states in which there is the least *scope* for error. This point is demonstrated by the “Simulated” column, which simulates choices using a fixed logit model for each state; this exercise shows us what the results would look like if all of the variation across states were due to variation in choice sets rather than variation in consumer behavior, and it is very close to the actual results. So even in the case of geographic variation, it appears that

the variation we document is driven largely by variation in choice set characteristics and not by heterogeneity across consumers in their ability to choose from a given choice set.

Our previous work documented several choice inconsistencies in Medicare Part D plan choice, and the results reported here suggest that they are pervasive: regardless of age, gender, predicted drug expenditures or the predictability of drug demand, consumers underweight out of pocket costs relative to premiums and fail to give sufficient attention to individualized aspects of plans; as a result, they frequently choose plans which are dominated in the sense that alternative plans provide better risk protection at lower cost. There is some evidence that choosing appropriate plans might be especially difficult for the sickest individuals.

## REFERENCES

- Abaluck, Jason, and Jon Gruber.** Forthcoming. “Choice Inconsistencies among the Elderly: Evidence from Plan Choice in the Medicare Part D Program.” *American Economic Review*.
- Duggan, Mark G., and Fiona Scott Morton.** 2011. “The Medium-Term Impact of Medicare Part D on Pharmaceutical Prices.” *American Economic Review*, 101(3): 387–392.
- Iyengar, Sheena S., and Eric Kamenica.** 2006. “Choice Overload and Simplicity Seeking.” Unpublished.